A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)



Status:Recruiting
Conditions:Neurology, Orthopedic
Therapuetic Areas:Neurology, Orthopedics / Podiatry
Healthy:No
Age Range:2 - 7
Updated:3/22/2019
Start Date:December 21, 2018
End Date:March 24, 2020
Contact:Mary Frances Harmon
Email:mharmon@ptcbio.com
Phone:(908) 912-9256

Use our guide to learn which trials are right for you!

Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren

This study is designed to evaluate the ability of ataluren to increase dystrophin protein
levels in muscle cells of participants with nmDMD. The study will evaluate the levels of
dystrophin before and after 40 weeks of ataluren therapy using muscle biopsies and two
validated assay methods, electrochemiluminescence (ECL) and immunohistochemistry.


Inclusion Criteria:

- Evidence of signed and dated informed consent/assent document(s) indicating that the
participant (and/or his parent/legal guardian) has been informed of all pertinent
aspects of the trial.

- Phenotypic evidence of duchenne muscular dystrophy (DMD) based on the onset of
characteristic clinical symptoms or signs (for example, proximal muscle weakness,
waddling gait, and Gowers' maneuver) and an elevated serum creatine kinase (CK).
Medical documentation of phenotypic evidence of DMD needs to be provided upon request
by the Sponsor's medical monitor.

- Documentation of the presence of a nonsense point mutation in the dystrophin gene as
determined by gene sequencing. Review and approval of documentation by sponsor or
designee is required prior to enrollment.

- Willing to undergo muscle biopsy.

Exclusion Criteria:

- Ongoing intravenous (IV) aminoglycoside or IV vancomycin therapy.

- Known contra-indication to muscle biopsy (such as bleeding or clotting disorders).

- Prior or ongoing therapy with ataluren.

- Known hypersensitivity to any of the ingredients or excipients of the study drug (for
example, refined polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C,
crospovidone XL10, hydroxyethyl cellulose, colloidal silica, magnesium stearate).

- Exposure to another investigational drug within 2 months prior to start of study
treatment, or ongoing participation in any interventional clinical trial.

- Requirement for daytime ventilator assistance or any use of invasive mechanical
ventilation via tracheostomy. Evening non-invasive mechanical ventilation such as use
of bilevel positive airway pressure (Bi-PAP) therapy is allowed.

- Elevated serum creatinine or cystatin C levels at screening.

- Prior or ongoing medical condition (for example, concomitant illness, psychiatric
condition, behavioral disorder), medical history, physical findings or laboratory
abnormality that, in the investigator's opinion, could adversely affect the safety of
the participant, makes it unlikely that the course of treatment or follow-up would be
completed, or could impair the assessment of study results.
We found this trial at
10
sites
3901 Rainbow Blvd
Kansas City, Kansas 66160
(913) 588-5000
Principal Investigator: Jeffrey Statland
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Principal Investigator: Peter Karachunski
Phone: 612-626-4690
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
630 W 168th St
New York, New York 10032
Principal Investigator: Darryl De Vivo
Phone: 212-342-3679
?
mi
from
New York, NY
Click here to add this to my saved trials
601 Children's Lane
Norfolk, Virginia 23507
(757) 668-7000
Principal Investigator: Crystal Proud
Phone: 757-469-9123
Children's Hospital of The King's Daughters Children
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Peter Heydemann
Phone: 312-942-0079
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
6621 Fannin St
Houston, Texas 77030
(832) 824-1000
Principal Investigator: Tim Lotze
Phone: 832-822-1255
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Stanley Nelson
Phone: 310-267-2416
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1919 E Thomas Rd
Phoenix, Arizona 85006
(602) 933-1000
Principal Investigator: Saunder Bernes
Phone: 602-933-0641
Phoenix Children's Hospital Phoenix Children's Hospital has provided hope, healing, and the best healthcare for...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Craig McDonald
Phone: 916-734-0968
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Ratna Bhavaraju-Sanka
Phone: 210-567-8222
?
mi
from
San Antonio, TX
Click here to add this to my saved trials